Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

GLP-1 drugs like Ozempic and Wegovy are game-changers for obesity, but they don't deliver the same results for everyone. Researchers at the University of Alberta are investigating whether "metabolic adaptation" — the body's hidden energy-saving mode — could explain why some people plateau or don't respond. Understanding this could pave the way for more personalized obesity treatment.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) have become cornerstones of obesity management, helping patients lose an average of 15% of their body weight over 68 weeks when combined with lifestyle changes. But the results are far from uniform — and scientists want to know why.
Researchers at the University of Alberta are zeroing in on metabolic adaptation, also called adaptive thermogenesis — a phenomenon where the body burns even fewer calories than expected during weight loss, like a light bulb automatically dimming to save electricity. They believe this "energy-saving mode," alongside factors like genetics, gut microbiota, body composition, age, and sex, may explain why some patients respond dramatically to semaglutide while others hit a frustrating plateau.
Their team is currently recruiting participants with insulin resistance or diabetes who are starting semaglutide, tracking changes in body composition and energy use over six months using a whole-room indirect calorimeter — a rare facility that precisely measures calorie burning at rest, after eating, and during exercise.
Key Takeaways:
Why it matters: As GLP-1 drugs become one of the most prescribed therapies in medicine, understanding why they work differently across patients is critical for moving toward truly personalized obesity care.